Monthly Injectable Buprenorphine for Methamphetamine Use Disorder (MURB)
The Research Need
Stimulants such as methamphetamine are currently contributing to the evolving opioid overdose crisis. Unlike the robust evidence that supports the use of medications for opioid use disorder, medications for methamphetamine use disorder with co-occurring opioid misuse are not yet available.
About the Program
This program will test the use of injectable extended-release buprenorphine to treat methamphetamine use disorder among individuals with opioid misuse that is not severe enough to warrant medications for opioid use disorder.
Immediate-release sublingual (under-the-tongue) buprenorphine is known to reduce stimulant use. The recent approval of extended-release buprenorphine injected under the skin expands the potential use of this medication and may improve the poor treatment adherence that has complicated medication trials.
This research will be conducted at four to six treatment sites participating in the National Drug Abuse Treatment Clinical Trials Network (CTN) that brings together medical and specialty treatment providers, researchers, patients, and the National Institute on Drug Abuse.
This 12-week randomized, double-blind, placebo-controlled trial will test injectable extended-release buprenorphine to treat methamphetamine use disorder among individuals with opioid misuse that is not severe enough to warrant medications for opioid use disorder.
Participating NIH Institutes, Centers, and Offices
View Other Research Programs in This Focus Area
- Collaborative Care for Polysubstance use in Primary Care Settings (Co-Care)
- Optimizing Care for People with Opioid Use Disorder and Mental Health Conditions
- Optimizing the Duration, Retention, and Discontinuation of Medication Treatment for Opioid Use Disorder
- Preventing Opioid Use Disorder
- Prevention of Progression to Moderate or Severe Opioid Use Disorder (STOP)
- Sleep Dysfunction as a Core Feature of Opioid Use Disorder and Recovery